ArticleScientific reports2025
Effect of delayed treatment on survival of patients with head and neck squamous cell cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prediction of Residual Disease in Unresectable Head and Neck Squamous Cell Carcinoma After Concurrent Chemoradiotherapy.World journal of oncology · 2026Article
- Article
- Missed Clinic Appointments for Human Papillomavirus-Related Oropharyngeal Cancer.Laryngoscope investigative otolaryngology · 2026Article
- Advanced Metastatic Laryngeal Carcinoma: A Case Report on Palliative Management in Primary Care.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The impact of prolonged treatment delays on the survival outcomes of patients with head and neck squamous cell cancer (HNSCC) remains controversial. Patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The association between diagnosis-to-treatment interval (DTI) and survival was assessed using Cox proportional hazards models and competing risk regression.4700 (6.1%) experienced treatment delays and 28,934 (37.8%) died due to cancer-specific causes. Treatment delays were associated with a worse overall survival (OS) and cancer-specific survival (CSS) of patients with cancer in the lip/oral cavity (OS: adjusted hazard ratio [aHR] = 1.16, 95% confidence interval [CI]: 1.08-1.24; CSS: aHR = 1.15, 95% CI 1.06-1.24), oropharynx (OS: aHR = 1.19, 95% CI 1.12-1.28; CSS: aHR = 1.19, 95% CI 1.10-1.28), and larynx (OS: aHR = 1.21, 95% CI 1.13-1.30; CSS: aHR = 1.21, 95% CI 1.10-1.33). However, treatment delay did not find significance on OS and CSS in patients with cancers of the hypopharynx, nasopharynx, nasal cavity and sinuses, or salivary glands at the time cutoff of 2 months for delayed treatment. Prolonged treatment delays were associated with an increased risk of mortality in patients with lip/oral cavity, oropharyngeal, and laryngeal cancers, and should be focused on in order to improve patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.